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To assess the therapeutic benefits of antidepressants in depressive women during and after menopausal 
transition, PubMed, Cochrane Library, EMBASE and Science Direct were systematically searched from 
inception to February 1, 2020 for randomized controlled trials examining antidepressants compared 
to placebo. Primary outcome was change in depressive symptom severity, while secondary outcomes 
were rates of response/remission rates and dropout/discontinuation due to adverse events. Seven trials 
involving 1,676 participants (mean age = 52.6 years) showed significant improvement in depressive 
symptoms (k = 7, Hedges’ g = 0.44, 95% confidence interval (CI) = 0.32 to 0.57, p < 0.001) relative to 
that in controls. Furthermore, response (k = 3, odds ratio (OR) = 2.53, 95% CI = 1.24 to 5.15, p = 0.01) 
and remission (k = 3, OR = 1.84, 95% CI = 1.32 to 2.57, p < 0.001) rates were significantly higher in 
antidepressant-treated groups compared to those with controls. Although dropout rates did not differ 
between antidepressant and control groups (k = 6, OR = 0.93, 95% CI = 0.70 to 1.26, p = 0.68), the rate 
of discontinuation due to adverse events was significantly higher in antidepressant-treated groups 
(k = 6, OR = 0.55, 95% CI = 0.35 to 0.86, p = 0.01). Subgroup analysis indicated that antidepressants 
were also efficacious for depressive symptoms in those without diagnosis of MDD. The results 
demonstrated that antidepressants were efficacious for women with depressive syndromes during and 
after menopausal transition but associated with a higher risk of discontinuation due to adverse events.
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Accumulating evidence indicates that women appear to be at a particularly higher risk of the emergence of major 
depressive disorder (MDD) and also depressive symptoms not severe enough to meet the diagnostic criteria of 
MDD during menopausal transition1. According to the Stages of Reproductive Aging Workshop (STRAW) stag-
ing system based on FSH level and regularity of menstrual cycle, the reproductive period of women can be divided 
into three phases (i.e., reproductive, menopausal transition, and postmenopause) starting from menarche2. With 
the final menstrual period (FMP) being set as the anchor, five stages occur before the FMP (i.e., three stages in 
the reproductive phase and two stages during menopausal transition), while there are two stages (i.e., early and 
late) in the postmenopausal phase. The STRAW staging system also indicates an overlapping period of one year 
of amenorrhea between perimenopause and postmenopause starting from the end of menopausal transition. In 
recent years, depression during menopausal transition is also considered to be a unique subtype of depression3; 
the accompanying somatic disorders, such as vasomotor symptoms (e.g., hot flashes and night sweats), changes 
in sexual function4, and sleep disturbances5, may contribute to the development of depressive symptoms or delay 
the recognition of affective disorders during this phase of the female reproductive cycle6.
The management of depressive symptoms among peri- and post-menopausal women can be challenging. For 
example, although some guidelines suggested hormone replacement therapy (HRT)7, other studies have reported 
concerns that may limit its widespread use, including controversial therapeutic benefits8, a possible increased 
risk of developing cancer7,9, and a high recurrence rate of depressive symptoms following the cessation of HRT10. 
Therefore, antidepressant agents may provide a clinically useful alternative for the management of depressive 
disorders during menopause. However, the results of previous studies in this population have been inconsistent, 
with different findings being reported in the beneficial effects of serotonin-norepinephrine reuptake inhibitors 
(SNRIs)11 and selective serotonin reuptake inhibitors (SSRIs)12. As a result, the Endocrine Society in the U.S. sug-
gests that antidepressants should only be used for the management of MDD during menopause7. Furthermore, 
depressive symptoms of severity less than that of MDD (i.e., subthreshold depression) have also been reported 
to be prevalent in this population, and an ever increasing body of evidence indicates that they have a detrimental 
impact on the quality of life and functioning during menopausal transition13,14. Certain guidelines endorsed the 
use of antidepressants or psychotherapy as frontline treatments for perimenopausal depression15. Nevertheless, 
evidence for the therapeutic benefits of antidepressants for menopausal women with subthreshold depressive 
symptoms is controversial16,17.
Therefore, the current study aimed at providing a comprehensive systematic review and meta-analysis 
of all randomized controlled clinical trials (RCTs) evaluating the effects of antidepressants in peri- and 
post-menopausal women with the whole spectrum of depressive disorders during menopausal transition. In 
addition, we aimed at: (1) assessing the therapeutic effects of antidepressant treatment in this population; (2) 
evaluating whether potential benefits of antidepressant agents differ in those with full-blown MDD compared to 
those experiencing subthreshold depression; and (3) investigating the safety and tolerability of antidepressants.
Methods
Guidelines and protocol. This systematic review and meta-analysis was conducted according to the guide-
lines presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement18 
(Supplementary Table S1). An a priori defined but unpublished protocol (available upon request to the authors) 
that was approved by the Institutional Review Board of Tri-Service General Hospital (TSGHIRB: B-105-12) was 
followed.
Search strategy and identification of eligible studies. Two investigators (YS Cheng and PT Tseng) 
independently searched the PubMed/MEDLINE, Cochrane Library, EMBASE and Science Direct electronic 
databases from inception to February 1, 2020, using the following keywords: (antidepressants and [perimen-
opause or postmenopause or menopause] and [depression or depressive disorder or mood]). In addition, the 
ClinicalTrials.gov database was searched using the following search string: ([antidepressant] AND [depression 
and menopause]). The search of PubMed/MEDLINE was limited to clinical trials. This search strategy was aug-
mented through a manual search of the reference lists of eligible articles as well as relevant clinical guidelines and 
review articles1,4,5,7–9,19.
Two authors (YS Cheng and PT Tseng) screened the titles and abstracts of retrieved references for eligibility. 
A list of potentially eligible studies was constructed by consensus, after which full-text examinations were con-
ducted. A third reviewer (CK Sun) was consulted if any inconsistencies arose.
Eligibility criteria. The inclusion criteria were: (1) peer-reviewed articles investigating the efficacy of anti-
depressants on depressive symptoms in menopausal women meeting the criteria for MDD or experiencing sub-
threshold depressive symptoms; and (2) articles that were controlled trials conducted in humans. No language 
restrictions were applied.
The exclusion criteria were: (1) animal studies; (2) trials not related to the treatment effect of antidepressants 
on depressive symptoms; and (3) studies without a placebo group (i.e., head-to-head trials).
Methodological quality appraisal. Two independent authors (YS Cheng and PT Tseng) evaluated the risk 
of bias (inter-rater reliability, 0.85) for each domain described in the Cochrane risk of bias tool20.
Primary outcome. The primary outcome measure was a change in the severity of depressive symptoms as 
rated by standard instruments used in each included study.
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Secondary outcomes. Secondary outcomes of interest included response and remission rates in each group. 
Treatment response was defined as a decrease of ≥50% from baseline depression rating scale score as applied in 
each study. Remission rate was defined as ≤7 points on the Hamilton-depression rating scale score, or ≤10 points 
on the Montgomery-Åsberg depression rating scale. We also evaluated the safety of the antidepressants consider-
ing dropout rates and the rate of discontinuation due to adverse events.
Data extraction and management. Two independent authors extracted data from the eligible studies 
into a database of pre-determined variables of interest, including mean age (years), mean body mass index (BMI), 
duration of antidepressant treatment (weeks), and ethnicity (Caucasian, African American, Hispanic, or Asian). 
The corresponding authors were contacted by email to request additional data on at least two different occasions 
1 week apart whenever variables of interest were not available.
Statistical analysis. Based on the presumed high heterogeneity among the included studies, data were 
analyzed using random-effects meta-analysis models rather than fixed effects models21 using Comprehensive 
Meta-Analysis software version 3 (Biostat, Englewood, NJ). Effect sizes (ESs) of changes in depressive symptoms 
between groups were analyzed using Hedges’ g and 95% confidence intervals (95% CIs). We calculated odds ratios 
(ORs) with 95% CIs for secondary outcomes using dichotomous items (such as response and remission rates).
Heterogeneity was evaluated using the Q statistic22, and the I2 statistic was used to evaluate the proportion of 
variation23. We examined publication bias by visually inspecting funnel plots when less than ten datasets were 
available24, while Egger’s regression test was used when ten or more independent datasets were available25. We 
performed the Duval and Tweedie trim and fill test to adjust ESs when evidence of publication bias was found26. 
With the automated program of Comprehensive Meta-Analysis software version 3, we arranged sensitivity anal-
ysis to verify whether an outlier could be biasing our ES estimates27. To be specific, to comprehensively evaluate 
the potential bias contributed to an outlier, we removed one study at a time from the analysis and completed the 
examination of potential bias contributed by each study included in the current study.
To evaluate potential sources of heterogeneity and confounding effects, we performed meta-regression and 
subgroup meta-analyses. Specifically, when there were at least ten datasets we conducted the meta-regression 
procedure using the unrestricted maximum likelihood method. Regarding subgroup meta-analysis, we focused 
on the studies that used SSRIs or SNRIs as the antidepressant agents, those that only included participants with 
a diagnosis of MDD; and trials that excluded participants with MDD [i.e., trials that assessed the effects of anti-
depressants on patients with subthreshold depressive symptoms (defined as those with depressive symptoms not 
severe enough to meet the diagnostic criteria of MDD)]. Furthermore, we performed subgroup analysis accord-
ing to the different depression rating scales that were used in the studies. Subgroup analyses were performed 
when data from at least three independent studies were provided28. Statistical significance was set at a two-tailed 
alpha level of 0.05.
Results
Study selection. The PRISMA flowchart used for study selection in this systematic review is shown in Fig. 1. 
After excluding duplicates, 42 full-text articles were assessed for eligibility. Among them, 35 were excluded due 
to the following reasons including: (1) No placebo (n = 27), (2) Duplicate sample source (n = 3), (3) Inclusion 
of participants not around time of menopause (n = 1), (4) Lack of adequate outcome measurement or baseline 
data for analysis (n = 3), and (5) Combination therapy, not just antidepressant (n = 1) [Supplementary Table S2]. 
Therefore, seven articles were eligible for the current meta-analysis (Table 1)11,12,16,17,29–31.
Figure 1. Flowchart of the Current Systematic Review and Meta-analysis.
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Author 
(year)Ref Menstrual status
Other 
diagnosis Criteria Design Comparison N
Duration 
(weeks) Outcome
Mean age 
(years) Country
Davari-
Tanha
(2016)29
Postmenopausal (STRAW staging system) N/A N/A RCT
Venlafaxine75  
mg/d 20
8 BDI (−) 51.0 IranCitalopram 
20 mg/d 20
Placebo 20
Macias-
Cortes
(2015)12
Peri-menopausal:
Change in cycle length  
of seven days or longer  
in either direction from the participant’s own 
baseline for at least two cycles, or
Late transition to menopause (i.e., three to 11 
MDD DSM-IV RCT
Fluoxetine 
20 mg/d 39
6
BDI (−)
HAM-D (+)
GS (−)
Response rate 
(HAM-D)
Remission rate 
49.2
Mexico
Placebo 37 48.8
Clayton
(2013)11
Peri- menopausal:
The presence of any  
of the following within 6 months before baseline:
1. Absolute change ≥7 days in menstrual cycle 
length, or
2. Change in menstrual flow amount (2 or more flow 
categories), or
3. Change in duration of menses (≥2 days), or
4. Amenorrhea lasting ≥3 months
OR
Post-menopausal:
1. Amenorrhea >12 months
2. Amenorrhea between 6–12 month with FSH > 40 
mIU/mL, or
3. Amenorrhea >6 months post bilateral 
oophorectomy
MDD DSM-IV RCT
Desvenlafaxine 
50 mg/d 185
10
HAM-D (+)
QIDS-SR
MADRS (+)
CGI-S
Response rate 
(HAM-D)
Remission rate 
(HAM-D)
Response rate 
(CGI-I)
53.2
USA
Placebo 178 52.8
Cheng
(2013)16
Menopausal:
1. Amenorrhea >12 months
2. Amenorrhea between 6–12 month with FSH > 40 
mIU/mL, or
3. Amenorrhea >6 months post bilateral 
oophorectomy)
N/A N/A RCT
Desvenlafaxine 
100 mg/day 153
12 POMS-TMDGS – depression (+) 53.4 USA
Desvenlafaxine 
150 mg/day 152
Placebo 153
Kornstein
(2010)30
Peri-menopausal:
The presence of any of the following  
within 6 months of baseline:
1. Absolute change of 7 days or more in menstrual 
cycle length, or
2. Change in menstrual flow amount (2 or more flow 
categories, e.g., from light or moderately light to 
moderately heavy or heavy), or
3. Change in duration of menses (absolute change of 
2 or more days); and periods of amenorrhea lasting 
at least 3 months.
OR
Post-menopausal:
1. Amenorrhea >12 months, or
2. Amenorrhea >6 months post bilateral 
oophorectomy)
MDD DSM-IV RCT
Desvenlafaxine 
100–200 mg/d 212
8
HAM-D (+)
QIDS-RS
MADRS 
 (+)
CGI-S
CGI-I
Response rate 
(HAM-D)
Remission rate 
(HAM-D)
Response rate 
(CGI-I)
52.0
USA
Placebo 109 53.0
Soares
(2008)31 Peri- or menopausal (STRAW staging system) N/A N/A RCT
Paroxetine  
25 mg/day 50 6 MADRS (+)
55.6
Canada
Placebo 50 57.0
Suvanto-
Luukkonen
(2005)17
Postmenopausal:
Amenorrhea >6 months with FSH > 30 IU/L) N/A N/A RCT
Fluoxetine  
20 mg/d 50
36 BDI (-)
54.0
FinlandCitalopram  
30 mg/day 49 54.0
Placebo 50 54.0
Table 1. Summary of characteristics of studies in the current meta-analysis. STRAW, Stages of Reproductive 
Aging Workshop; MDD, major depressive disorder; N/A, information not available; DSM-IV, Diagnostic 
and Statistical Manual of Mental Disorders (Fourth Edition); RCT, randomized controlled trial; BDI, beck 
depression inventory; HAM-D, Hamilton Depression Rating Scale; GS, Greene Scale; QIDS-SR, quick inventory 
of depressive symptomatology; MADRS, Montgomery–Åsberg depression rating scale; CGI-S, clinical global 
impression-severity; CGI-I, clinical global impression-improvement.
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Among the seven eligible articles, data from 992 participants who received antidepressants (mean age = 52.7 
years, mean treatment duration = 9.5 weeks) and 684 participants who received a placebo (mean age = 52.5 
years) were synthesized. All seven studies prohibited the use of any medications or hormone therapies thought to 
relieve menopausal symptoms or depression in the control groups. Of the seven studies, three recruited partici-
pants with a baseline definite diagnosis of MDD11,12,29, three excluded participants with baseline MDD16,17,31, and 
the other did not set any limitation regarding baseline MDD (i.e. included participants with the whole depressive 
spectrum)29. Regarding the antidepressants that were investigated in each RCT, most studies investigated only one 
antidepressant, including desvenlafaxine in three11,16,30, fluoxetine in one12, and paroxetine in one28. In addition, 
in the study by Cheng (2013), the authors included two antidepressant-treated groups with different dosages of 
desvenlafaxine16. The other two studies investigated two antidepressants at the same time, one with citalopram 
and fluoxetine14 and the other one with citalopram and venlafaxine29.
Methodological quality of the included studies. Overall, we found that 65.3% (32/49 items), 22.5% 
(11/49 items), and 12.2% (6/49 items) of the included studies had a low, unclear, and high risk of bias, respectively. 
Unclear reporting of the allocation procedure or attrition bias of the studies further contributed to the risk of bias 
(Supplementary Table S4).
Primary outcome. The seven eligible studies included ten antidepressant-treated groups evaluating changes 
in the severity of depressive symptoms11,12,16,17,29–31, The meta-analysis showed that the participants randomized 
to receive antidepressants had a greater decrease in depressive symptoms relative to those who received a pla-
cebo (k = 7, Hedges’ g = 0.44, 95% CI = 0.32 to 0.57, p < 0.001) (Fig. 2) without significant heterogeneity (Q 
value = 13.73, df = 9, I2 = 34.43%, p = 0.13) or publication bias via Egger’s regression (t = 0.98, df = 8, p = 0.36). 
Sensitivity analysis where one study was excluded from analysis at a time revealed that no outlier among the 
included studies was biasing the overall ES estimates.
Few moderators could be tested in meta-regression analysis due to the limited number of independent data-
sets. Mean age (p = 0.06) and treatment duration (p = 0.10) did not appear to moderate the overall effect of anti-
depressants on depressive symptoms.
Subgroup analysis suggested that the participants randomized to receive either SSRIs (k = 4, Hedges’ g = 0.46, 
95% CI = 0.20 to 0.73, p < 0.001) or SNRIs (k = 4, Hedges’ g = 0.43, 95% CI = 0.28 to 0.58, p < 0.001) had a signif-
icantly higher overall improvement in depressive symptoms relative to those receiving a placebo. Furthermore, 
the beneficial effects of antidepressants were also evident when only studies that excluded participants with MDD 
at baseline were considered (k = 3, Hedges’ g = 0.37, 95% CI = 0.24 to 0.51, p < 0.001).
Secondary outcomes. Response rate. When focusing on the three studies that provided data regarding 
response rates11,12,30, the current meta-analysis found that the participants randomized to receive antidepres-
sants had a higher overall response rate than those who received a placebo (k = 3, OR = 2.53, 95% CI = 1.24 to 
5.15, p = 0.01) (Fig. 3). There was, however, very large and significant heterogeneity (Q value = 9.58, df = 2, 
I2 = 79.12%, p = 0.01), and funnel plot inspection suggested publication bias (Fig. 4A). After adjusting for pub-
lication bias using Duval and Tweedie’s trim and fill procedure, the ES was rendered non-significant (adjusted 
OR = 1.40, 95% CI = 0.66 to 2.99).
Remission rate. Three included studies provided data regarding remission rates11,12,30. The meta-analysis showed 
that the participants receiving antidepressants had a higher remission rate than the controls (k = 3, OR = 1.84, 
95% CI = 1.32 to 2.57, p < 0.001) (Fig. 3) without significant heterogeneity (Q value = 1.85, df = 2, I2 < 0.001%, 
p = 0.40) but significant publication bias via inspection of the funnel plot (Fig. 4B). The adjusted ESs using Duval 
and Tweedie’s trim and fill test remained statistically significant (adjusted OR = 1.50, 95% CI = 1.01 to 2.22).
Dropout rate. Six studies including eight antidepressant treatment groups provided data regarding dropout 
rates11,12,16,17,30,31. No significant differences in overall dropout rate were found between the participants receiv-
ing antidepressants relative to those receiving a placebo (k = 8, OR = 0.94, 95% CI = 0.70 to 1.26, p = 0.68) 
(Fig. 5). Furthermore, no significant heterogeneity (Q value = 8.33, df = 7, I2 < 16.0%, p = 0.30) was observed. 
However, inspection of the funnel plot suggested the presence of publication bias (Fig. 4C), although this ES 
remained non-significant after adjusting using Duval and Tweedie’s trim and fill procedure (adjusted OR = 0.91, 
95% CI = 0.66 to 1.26). Of the seven studies having mentioned the dropout rates, five gave reasons for dropouts 
(Supplementary Table S3). For the treatment group, the reasons were adverse effects in four studies and ineffec-
tiveness in another study. For the control groups, ineffectiveness was reported in three studies, while adverse 
effects and patient’s request were the reasons for dropouts in the other two studies, respectively.
In subgroup analysis, dropout rates were similar between the participants randomized to receive SSRIs com-
pared to those receiving a placebo (k = 3, OR = 1.25, 95% CI = 0.76 to 2.07, p = 0.38). In addition, dropout rates 
were similar among the participants treated with SNRIs compared to those randomized to receive a placebo 
(k = 3, OR = 0.82, 95% CI = 0.57 to 1.19, p = 0.31).
Discontinuation rate due to adverse events. Six studies (seven antidepressant-treatment groups) provided data 
on discontinuation due to adverse events11,12,16,17,30,31. A significantly higher overall discontinuation rate due to 
adverse events was observed among the participants randomized to receive antidepressants relative to those 
receiving a placebo (k = 6, OR = 0.55, 95% CI = 0.35 to 0.86, p = 0.01) (Fig. 5) without significant heterogene-
ity (Q value = 1.30, df = 6, I2 < 0.001%, p = 0.97). The inspection of the funnel plot (Fig. 4D) suggested the 
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possibility of publication bias. Nevertheless, the adjusted overall ES for this outcome remained statistically signif-
icant (adjusted OR = 0.56, 95% CI = 0.36 to 0.87).
In subgroup analysis, the discontinuation rate due to adverse events was similar between the participants who 
received SSRIs and those who received a placebo (k = 3, OR = 0.62, 95% CI = 0.26 to 1.51, p = 0.30). However, 
the discontinuation rate due to adverse events was higher in the participants who received SNRIs compared to 
those randomized to receive a placebo (k = 3, OR = 0.53, 95% CI = 0.31 to 0.89, p = 0.02). The side effects were 
mostly mild as assessed by the study investigators with the most common being nausea, dry mouth and headache 
in the antidepressant groups. Detailed information about the adverse events addressed in the included studies is 
summarized in Supplementary Table S3.
Discussion
The results of the current meta-analysis were derived from seven RCTs including data from 1,676 participants, 
and suggested that antidepressant drug treatment, either with SSRIs or SNRIs, was efficacious for the manage-
ment of depressive symptoms across the full spectrum of depressive disorders presenting during or after men-
opausal transition. Our results also suggested that antidepressant treatment during menopause was associated 
with higher response and remission rates compared to placebo. Furthermore, antidepressant treatment was not 
associated with higher dropout rates compared to placebo, although discontinuation rates due to adverse events 
were higher among the participants randomized to receive antidepressant compared to placebo. To the best of 
our knowledge, the current study is the first to try to synthesize evidence from RCTs on the efficacy, safety and 
tolerability of antidepressants for the treatment of depressive spectrum disorders during and after menopausal 
transition.
The present study had its strengths and limitations. Due the availability and inclusion of seven unique RCTs, 
we were able to perform a meta-analysis and investigate factors that may influence the therapeutic effects of 
antidepressants among peri- and post-menopausal women. Our results suggested that antidepressants could be 
efficacious for women who developed MDD during or after menopausal transition as well as for those presenting 
with subthreshold depressive symptoms. This is particularly relevant because cross-sectional and prospective 
studies have indicated that depressive symptoms in this population appear to occur on a continuum of sever-
ity14,32,33. Moreover, subthreshold depression may significantly impair the quality of life and functioning of this 
population14, which may also increase the risk of MDD in a subset of women during or after menopausal transi-
tion32,33. Furthermore, most of the studies seemed to have fair quality, while there was only dominant unclear risk 
in the item of allocation concealment. However, most of the studies were conducted in North America, with only 
one from the Middle East29 and one from North Europe17. Therefore, extrapolation of the results to other popu-
lations may not be justified. In addition, treatment with antidepressants was associated with a higher likelihood 
of achieving response and remission relative to a placebo. However, there was evidence of publication bias on the 
Figure 2. Forest plot of changes in depressive symptoms in menopausal women with antidepressant treatments 
compared to those without. Note significantly better improvements in severity of depressive symptoms (k = 10, 
Hedges’ g = 0.44, 95% CI = 0.32 to 0.57, p < 0.001) in subjects receiving antidepressants compared to that in 
controls.
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overall effects of antidepressants on treatment response, and hence the results should be interpreted with caution 
since this effect was rendered non-significant following adjustments for publication bias. It is also worth noting 
that only three trials provided data regarding response and remission rates.
Moreover, as in most meta-analyses, another limitation of the current study was the heterogeneity of the 
included studies in terms of study duration, drug dosage, the use of different depression scales and different ver-
sions (e.g., Hamilton depression rating scale). Therefore, we performed subgroup analysis and meta-regression to 
investigate how different factors may affect the study results. Meta-regression showed that certain factors such as 
duration and age did not affect our results, and our subgroup analysis demonstrated that antidepressant treatment 
was still effective for those suffering from subthreshold depression. Nevertheless, the number of studies was too 
small to allow other meaningful subgrouping or meta-regression analyses. Besides, there was heterogeneity in 
some estimates, the sources of which were explored through subgroup and meta-regression analyses. However, 
due to the relatively small number of studies, the results from these analyses should be regarded as exploratory 
Figure 3. Forest plots of response and remission rates in menopausal women with antidepressant treatments 
compared to that in controls. Note significantly better response rate (k = 3, OR = 2.53, 95% CI = 1.24 to 5.15, 
p = 0.01) and remission rate (k = 3, OR = 1.84, 95% CI = 1.32 to 2.57, p < 0.001) in menopausal women with 
antidepressants than those in the controls.
Figure 4. Funnel plots of meta-analysis on (A) response rate; (B) remission rate; (C) dropout rate, and (D) 
adverse event-related discontinuation rate.
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instead of conclusive. Furthermore, in recent years, perimenopausal depression is considered a distinct sub-
type of depression that warrants a unique rating scale for evaluation3. Nevertheless, most studies in the present 
meta-analysis were old and did not use criteria specified for perimenopausal depression3. The issue was further 
complicated by the fact that most studies included a mixed population of women during menopausal transition 
and in the postmenopausal phase. Therefore, whether the instruments reported in those studies could capture the 
complex symptoms of perimenopausal depression remains to be elucidated. Finally, the overall body of evidence 
remains limited in this area.
Because the treatment of depression during menopause remains a clinical challenge, the findings of the pres-
ent study had its clinical implications. The current meta-analysis indicates that antidepressants could be effica-
cious for the treatment of this condition in this vulnerability period of the female reproductive cycle. However, 
only three RCTs included participants with a definite diagnosis of MDD11,12,30. An evidence-based psychother-
apeutic approach for depression (e.g., cognitive behavioral therapy or interpersonal therapy) could initially be 
offered to menopausal women with subthreshold depression, although the evidence base for this practice has 
mostly been extrapolated from psychotherapeutic trials that have been conducted in general cases of depression14. 
Interestingly, we did not identify any RCTs on the effects of tricyclic antidepressant agents in postmenopausal 
women with depression. Therefore, this meta-analysis provides evidence for the use of SSRIs and SNRIs as treat-
ments for depression in this population. Specifically, the antidepressants fluoxetine12,17, citalopram17,29, paroxe-
tine31, desvenlafaxine11,16,30 and venlafaxine29 were tested across the included RCTs. Further research is warranted 
to investigate the effects of other antidepressants in this population.
There was no significant difference in dropout rate between the participants treated with antidepressants and 
those who received a placebo. However, antidepressant treatment was associated with a greater likelihood of 
discontinuation due to adverse events. This is consistent with an increasing number of studies that have raised 
concerns regarding the safety and tolerability of newer generation antidepressants, including SSRIs and SNRIs34. 
Such concerns should be weighed when considering the use of antidepressants, especially for women during or 
after menopausal transition with less severe forms of depression35.
The current systematic review and meta-analysis may provide new directions for research. First, only acute 
antidepressant trials were identified. However, depressive disorders in postmenopausal women appear to have 
Figure 5. Forest plots of safety profile of antidepressants reflected by dropout rate and rate of study 
discontinuation due to adverse events in menopausal women with antidepressants and in those without. Note 
the non-significant difference in dropout rate between the two groups (k = 7, OR = 0.55, 95% CI = 0.35 to 0.86, 
p = 0.01) and significantly higher Dis AE rate in the subjects receiving antidepressants than those receiving 
placebos (k = 5, Hedges’ g = 0.25, 95% CI = 0.02 to 0.48, p = 0.03). Abbreviations: CI, confidence interval; Dis 
AE, study discontinuation due to adverse events; MA, meta-analysis; MDD, major depressive disorder; OR: 
odds ratio.
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heterogenous symptom trajectories32,33, and further investigations are warranted to investigate the benefits 
of maintenance treatment with antidepressants for depressive disorders in this population (i.e., the design of 
long-term RCTs). In addition, our subgroup analysis suggested that SNRIs but not SSRIs were associated with 
higher discontinuation rates due to adverse events relative to a placebo. However, further RCTs are needed to 
confirm this finding. It has been suggested that the presence of vasomotor symptoms during menopause may 
contribute to the development and persistence of depressive disorders during this phase of the female reproduc-
tive cycle14, and also that low-dose paroxetine and SNRIs could improve these symptoms36. Therefore, further 
research is needed to investigate whether the amelioration of vasomotor disturbances could contribute to the 
beneficial effects of antidepressants seen in the current study. Finally, the evidence base regarding options for the 
treatment of depressive disorders during menopause remains limited. The design of new RCTs is a necessary step 
before firm conclusions regarding the comparative efficacy and tolerability of various pharmacological treatments 
can be made.
conclusions
The current systematic review and meta-analysis provides evidence that antidepressants are effective for the treat-
ment of depressive disorders for women during and after menopausal transition. Long-term RCTs are required to 
investigate the efficacy, safety, and tolerability of maintenance treatment with antidepressants during menopause.
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Received: 23 September 2019; Accepted: 19 March 2020;
Published: xx xx xxxx
References
 1. Georgakis, M. K. et al. Association of age at menopause and duration of reproductive period with depression after menopause: A 
systematic review and meta-analysis. JAMA Psychiatry 73, 139–149, https://doi.org/10.1001/jamapsychiatry.2015.2653 (2016).
 2. Soules, M. R. et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil. Steril. 76, 874–878, https://doi.
org/10.1016/s0015-0282(01)02909-0 (2001).
 3. Kulkarni, J. et al. Development and validation of a new rating scale for perimenopausal depression-the Meno-D. Transl. Psychiatry 
8, 123, https://doi.org/10.1038/s41398-018-0172-0 (2018).
 4. Nazarpour, S., Simbar, M. & Tehrani, F. R. Factors affecting sexual function in menopause: A review article. Taiwan. J. Obstet. 
Gynecol. 55, 480–487, https://doi.org/10.1016/j.tjog.2016.06.001 (2016).
 5. Baker, F. C., de Zambotti, M., Colrain, I. M. & Bei, B. Sleep problems during the menopausal transition: prevalence, impact, and 
management challenges. Nat. Sci. Sleep. 10, 73–95, https://doi.org/10.2147/NSS.S125807 (2018).
 6. Bungay, G. T., Vessey, M. P. & McPherson, C. K. Study of symptoms in middle life with special reference to the menopause. Br. Med. 
J. 281, 181–183, https://doi.org/10.1136/bmj.281.6234.181 (1980).
 7. Stuenkel, C. A. et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J. Clin. 
Endocrinol. Metab. 100, 3975–4011, https://doi.org/10.1210/jc.2015-2236 (2015).
 8. Whedon, J. M., KizhakkeVeettil, A., Rugo, N. A. & Kieffer, K. A. Bioidentical estrogen for menopausal depressive symptoms: A 
systematic review and meta-analysis. J. Womens Health 26, 18–28, https://doi.org/10.1089/jwh.2015.5628 (2017).
 9. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the 
Women’s Health Initiative randomized controlled trial. JAMA 288, 321–333, https://doi.org/10.1001/jama.288.3.321 (2002).
 10. Ness, J., Aronow, W. S. & Beck, G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 53, 356–361, 
https://doi.org/10.1016/j.maturitas.2005.06.008 (2006).
 11. Clayton, A. H. et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and 
postmenopausal women with major depressive disorder. J. Clin. Psychiatry 74, 1010–1017, https://doi.org/10.4088/JCP.12m08065 
(2013).
 12. Macias-Cortes Edel, C., Llanes-Gonzalez, L., Aguilar-Faisal, L. & Asbun-Bojalil, J. Individualized homeopathic treatment and 
fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, 
double-dummy, double-blind, placebo-controlled trial. PLoS One 10, e0118440, https://doi.org/10.1371/journal.pone.0118440 
(2015).
 13. Vivian-Taylor, J. & Hickey, M. Menopause and depression: is there a link? Maturitas 79, 142–146 (2014).
 14. Soares, C. N. Depression and Menopause: Current Knowledge and Clinical Recommendations for a Critical Window. Psychiatr. 
Clin. North. Am. 40, 239–254, https://doi.org/10.1016/j.psc.2017.01.007 (2017).
 15. Maki, P. M. et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. 
Menopause 25, 1069–1085, https://doi.org/10.1097/GME.0000000000001174 (2018).
 16. Cheng, R. J. et al. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe 
vasomotor symptoms. Climacteric 16, 17–27, https://doi.org/10.3109/13697137.2012.672495 (2013).
 17. Suvanto-Luukkonen, E. et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 
9-month, placebo-controlled, double-blind study. Menopause 12, 18–26 (2005).
 18. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. & PRISMA Group. Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. PLoS Med. 6, e1000097, https://doi.org/10.1371/journal.pmed.1000097 (2009).
 19. Yasui, T. et al. Changes in circulating cytokine levels in midlife women with psychological symptoms with selective serotonin 
reuptake inhibitor and Japanese traditional medicine. Maturitas 62, 146–152, https://doi.org/10.1016/j.maturitas.2008.12.007 
(2009).
 20. Higgins, J. P. T. et al. (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 
Available from www.training.cochrane.org/handbook (2019).
 21. Borenstein, M., Hedges, L. V., Higgins, J. P. & Rothstein, H. R. A basic introduction to fixed-effect and random-effects models for 
meta-analysis. Res. Synth. Methods 1, 97–111, https://doi.org/10.1002/jrsm.12 (2010).
 22. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002).
 23. Borenstein, M., Higgins, J. P., Hedges, L. V. & Rothstein, H. R. Basics of meta-analysis: I2 is not an absolute measure of heterogeneity. 
Res. Synth. Methods 8, 5–18, https://doi.org/10.1002/jrsm.1230 (2017).
1 0Scientific RepoRtS |         (2020) 10:8026  | https://doi.org/10.1038/s41598-020-64910-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 24. Higgins, J. P. & Green, S. 10.4.3.1 Recommendations on testing for funnel plot asymmetry. In: Higgins JP, Green S, editors. Cochrane 
Handbook for Systematic Reviews of Interventions. 5.1.0 ed: Cochrane Library (2011).
 25. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634, 
https://doi.org/10.1136/bmj.315.7109.629 (1997).
 26. Duval, S. & Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-
analysis. Biometrics 56, 455–463 (2000).
 27. Tobias, A. Assessing the influence of a single study in meta-analysis. Stata Tech. Bull. 8, 15–17 (1999).
 28. Davey, J., Turner, R. M., Clarke, M. J. & Higgins, J. P. Characteristics of meta-analyses and their component studies in the Cochrane 
Database of Systematic Reviews: a cross-sectional, descriptive analysis. BMC Med. Res. Methodol. 11, 160, https://doi.
org/10.1186/1471-2288-11-160 (2011).
 29. Davari-Tanha, F. et al. Comparison of citalopram and venlafaxine’s role in treating sleep disturbances in menopausal women, a 
randomized, double-blind, placebo-controlled trial. Arch. Gynecol. Obstet. 293, 1007–1013, https://doi.org/10.1007/s00404-015-
3900-1 (2016).
 30. Kornstein, S. G., Jiang, Q., Reddy, S., Musgnung, J. J. & Guico-Pabia, C. J. Short-term efficacy and safety of desvenlafaxine in a 
randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J. Clin. 
Psychiatry 71, 1088–1096, https://doi.org/10.4088/JCP.10m06018blu (2010).
 31. Soares, C. N. et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am. J. Med. 121, 159–162 
e1, https://doi.org/10.1016/j.amjmed.2007.10.007 (2008).
 32. Bromberger, J. T., Kravitz, H. M., Youk, A., Schott, L. L. & Joffe, H. Patterns of depressive disorders across 13 years and their 
determinants among midlife women: SWAN mental health study. J. Affect. Disord. 206, 31–40, https://doi.org/10.1016/j.
jad.2016.07.005 (2016).
 33. Hickey., M., Schoenaker, D. A., Joffe, H. & Mishra, G. D. Depressive symptoms across the menopause transition: findings from a 
large population-based cohort study. Menopause 23, 1287–1293, https://doi.org/10.1097/GME.0000000000000712 (2016).
 34. Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E. & Fava, G. A. The Safety, Tolerability and Risks Associated with the Use of 
Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother. Psychosom. 85, 270–288, https://doi.
org/10.1159/000447034 (2016).
 35. Fava, G. A. Rational use of antidepressant drugs. Psychother. Psychosom. 83, 197–204, https://doi.org/10.1159/000362803 (2014).
 36. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American 
Menopause Society. Menopause 22, 1155–1172; quiz 73–74, https://doi.org/10.1097/GME.0000000000000546 (2015).
Author contributions
C.-K.W., P.-T.T. and M.-K.W contributed equally as first authors and conceived the study. Y.-S.C., C.-K.S., D.-
J.L., T.-Y.C., F.-C.K., B.S., A.F.C., Y.-W.C. and P.-Y.L. all contributed to study design and literature review. P.-
T.T. and Y.-S.C. were responsible for data analysis. C.-K.S. and Y.-S.C. wrote the draft of the manuscript. Y.-S.C. 
and C.-K.S. both contributed as corresponding authors and took responsibility for revising and submitting the 
manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-64910-8.
Correspondence and requests for materials should be addressed to Y.-S.C. or C.-K.S.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
